PEGPH20: Phase Ib/II started

Halozyme and Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) began an open-label Phase Ib/II trial to compare PEGPH20 plus Halaven eribulin vs. Halaven alone in about 96 patients. The Phase I portion will...